<DOC>
	<DOCNO>NCT01598298</DOCNO>
	<brief_summary>RATIONALE : Duloxetine hydrochloride may lessen muscle , bone , joint pain cause hormone therapy . It yet know whether duloxetine hydrochloride effective placebo treat patient muscle , bone , joint pain cause hormone therapy . PURPOSE : This randomized phase III trial study well duloxetine hydrochloride work compare placebo treat muscle , bone , joint pain patient early-stage breast cancer receive hormone therapy .</brief_summary>
	<brief_title>S1202 : Duloxetine Hydrochloride Treat Muscle , Bone , Joint Pain Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether daily duloxetine hydrochloride ( duloxetine ) decrease average joint pain woman aromatase inhibitor-associated musculoskeletal syndrome ( AIMSS ) , measure 12 week modify Brief Pain Inventory Short Form ( BPI-SF ) . Secondary - To assess whether daily duloxetine decrease worst joint pain woman AIMSS , measure 12 week modify BPI-SF . - To assess whether daily duloxetine decrease pain interference woman AIMSS , measure 12 week modify BPI-SF . - To investigate whether daily duloxetine improve function , pain , stiffness knees/hips accord Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) scale . ( Exploratory ) - To investigate whether daily duloxetine improve function , pain , stiffness hand accord Modified Score Assessment Quantification Chronic Rheumatoid Affections Hands ( M-SACRAH ) . ( Exploratory ) - To investigate whether daily duloxetine improve functional quality life measure Functional Assessment Cancer Therapy-Endocrine Scale ( FACT-ES ) . ( Exploratory ) - To investigate whether daily duloxetine improve proportion patient report change well versus worst measure Global Rating Change Scale . ( Exploratory ) - To investigate whether daily duloxetine decrease analgesic use . - To investigate whether daily duloxetine increase adherence , reduce discontinuation rate , aromatase inhibitor ( AI ) therapy . ( Exploratory ) - To assess whether patient receive duloxetine compare placebo improve depression measure Patient Health Questionnaire ( PHQ-9 ) Weeks 6 12 . ( Exploratory ) - To explore relationship inherited variant gene responsible duloxetine metabolism activity ( COMT , HTR3A , SLC6A2 , SLC6A4 , CYP1A2 , CYP2D6 ) aromatase ( CYP19A1 ) change pain 12 week treatment . ( Exploratory ) - To explore impact treatment serum inflammatory cytokine level 12 week treatment baseline 12 week . ( Exploratory ) - To bank blood sample future correlative analysis . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord baseline pain score ( 4-6 v 7-10 ) , prior taxane use ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive duloxetine hydrochloride orally ( PO ) daily ( QD ) day 1-7 , twice daily ( BID ) day 8-84 , QD day 85-91 . - Arm II : Patients receive placebo PO QD day 1-7 , BID day 8-84 , QD day 85-91 . Patients complete modified Brief Pain Inventory Short Form ( BPI-SF ) questionnaire baseline periodically study treatment . Patients may also complete Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) scale , Modified Score Assessment Quantification Chronic Rheumatoid Affections Hands ( M-SACRAH ) , Functional Assessment Cancer Therapy-Endocrine Scale ( FACT-ES ) , Global Rating Change Scale , patient Health Questionnaire ( PHQ-9 ) . Patients undergo blood sample collection baseline periodically treatment correlative study , include biomarker genetic study . After completion study treatment , patient follow 168 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must woman histologically confirm estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) positive invasive carcinoma breast evidence metastatic disease ( M0 ) Patients must complete mastectomy breastsparing surgery must recover side effect surgery Patients must aromatase inhibitor ( AI ) associate musculoskeletal symptom begin increased start AI therapy ; new musculoskeletal pain must due specifically fracture traumatic injury Patients must complete S1202 Brief Pain InventoryShort Form ( BPISF ) within 7 day prior registration ; patient must `` average pain '' least 4 BPISF PATIENT CHARACTERISTICS : Patients must postmenopausal , define least one following : At least 12 month since last menstrual period Prior bilateral oophorectomy Previous hysterectomy one ovaries leave place ( previous hysterectomy documentation bilateral oophorectomy unavailable ) AND folliclestimulating hormone ( FSH ) value consistent institutional normal value post menopausal state ; patient age 55 , FSH level must obtain within 28 day prior registration OR Have LHRH agonist therapy least 3 month estradiol level draw within 28 day prior registration consistent institutional normal value postmenopausal state . Patients must Zubrod performance status 02 Patients must know allergy hypersensitivity duloxetine inactive ingredient match placebo Patients must contraindicate concurrent illness list duloxetine package insert include : Current primary psychiatric diagnosis ( schizophrenia , psychosis ) suicidal ideation , history bipolar disorder , seizure disorder History alcohol substance abuse dependence within 365 day prior registration Chronic liver disease Endstage renal disease Uncontrolled narrowangle glaucoma Clinically significant coagulation disorder Creatinine clearance &gt; 30 mL/min Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) within 3 x upper limit normal Total bilirubin within upper limit normal Patients must able complete study questionnaire English Spanish Patients must concurrent medical/arthritic disease could confound interfere evaluation pain efficacy include : inflammatory arthritis ( rheumatoid arthritis , systemic lupus , spondyloarthropathy , psoriatic arthritis , polymyalgia rheumatica ) , cancer involve bone Patients must willing submit blood sample correlative study ; baseline sample must obtain prior begin protocol treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics If patient treat chemotherapy and/or radiation therapy , treatment must complete least 28 day prior study registration Concurrent bisphosphonate trastuzumab therapy allow Patients recover Grade 2 high side effect chemotherapy and/or radiation therapy exception alopecia peripheral neuropathy Patients must currently take one follow aromatase inhibitor ( AI ) dose least 21 day , longer 12 month , prior registration plan continue least additional 180 day registration Anastrozole ( Arimidex® ) 1 mg daily Letrozole ( Femara® ) 2.5 mg daily Exemestane ( Aromasin® ) 25 mg daily Patients must take contraindicated medication list duloxetine package insert include follow : treatment phenothiazine , propafenone , flecainide , linezolid ; treatment monoamine oxidase ( MAO ) inhibitor within 14 day prior registration ; current use anticoagulation medication ( e.g. , heparin , warfarin ) Patients must require selective serotonin reuptake inhibitor ( SSRIs ) , serotonin norepinephirine reuptake inhibitor ( SNRIs ) , tricyclic antidepressant study participation ; patient must able taper discontinue treatment medication least 7 day prior registration ; patient must take duloxetine milnacipran within 90 day prior registration Patients receive treatment narcotic , tramadol , gabapentin , and/or pregabalin must take stable dose least 30 day prior registration</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>pain</keyword>
	<keyword>musculoskeletal complication</keyword>
</DOC>